Acute myeloid leukemia (AML) is characterized by chromosome abnormalities and somatic mutations in many genes that contribute to the pathogenesis and progression of the disease. This targeted, next generation sequencing test provides information on commonly mutated genes that have been identified as important prognostic and predictive markers, as well as targets for AML therapy.

Methodology and reporting:

Next generation sequencing is performed on DNA extracted from whole blood or bone marrow. This test is a targeted assay encompassing 10 genes (NPM1, CEBPA, FLT3, DNMT3A, IDH1, IDH2, RUNX1, ASXL1, KIT, JAK2) with variable full exon, full gene, or partial region coverage (depending on the specific locus). This assay will not detect genetic abnormalities outside the targeted regions. This test detects base substitutions, small insertions and deletions. This test does not detect large-scale changes and copy number variations. For FLT3 only testing by PCR (TAT three – seven days), please order “FLT3 ITD and TKD Mutation Test.”

An interpretive report will be provided.

Effective date: July 25, 2018

Specimen requirement and testing information:

Specimen: One (1) 4 mL whole blood or bone marrow in EDTA (lavender) tube

Test methodology: Next Generation Sequencing

Test code: AML10

Stability:
Refrigerated: up to five days from collection date (for blood and bone marrow)
Frozen: up to five days from collection date (for blood and bone marrow)

Turnaround time (TAT):
STAT: N/A
Routine: 10 - 14 days
Set-up days: Once a week

Rejection criteria: Gross hemolysis or large blood clots

References: Click here

A summary of all tests offered by our laboratory services can be found here:
http://www.pathology.uci.edu/services/index.asp

Sincerely,

Jeff Chan, MD, PhD
Director, Diagnostic Molecular Pathology Laboratory

Edwin S. Monuki, MD, PhD
Chair, Department of Pathology & Laboratory Medicine